Drug Type T-lymphocyte cell therapy |
Synonyms CMVspecific T cell therapy AlloVir, Cytomegalovirus-specific T cells (AlloVir), Cytomegalovirusspecific T cell therapy AlloVir + [4] |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Regenerative Medicine Advanced Therapy (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenoviridae Infections | Phase 3 | Australia | 24 Mar 2022 | |
Adenoviridae Infections | Phase 3 | France | 24 Mar 2022 | |
BK virus infection | Phase 3 | United States | 18 Mar 2021 | |
BK virus infection | Phase 3 | France | 18 Mar 2021 | |
BK virus infection | Phase 3 | Italy | 18 Mar 2021 | |
BK virus infection | Phase 3 | South Korea | 18 Mar 2021 | |
BK virus infection | Phase 3 | Spain | 18 Mar 2021 | |
BK virus infection | Phase 3 | Sweden | 18 Mar 2021 | |
BK virus infection | Phase 3 | United Kingdom | 18 Mar 2021 | |
Hemorrhagic cystitis | Phase 3 | United States | 18 Mar 2021 |
Phase 2 | 61 | Placebo (visually identical to Posoleucel) | aqdrwqmanb = bvjwnpnmqs yoaokvctih (cdtbukoaac, uielkefqbf - zidfowvvmm) View more | - | 16 May 2024 | ||
Phase 2/3 | 451 | (Posoleucel (ALVR105)) | dnljvzexhc(ewujmftzvv) = tqhrpevgle eluakjicqm (nptfqifyba, 0.44) View more | - | 16 May 2024 | ||
Placebo (Placebo) | dnljvzexhc(ewujmftzvv) = pyaowuctlq eluakjicqm (nptfqifyba, 0.42) View more | ||||||
Phase 3 | 97 | (Posoleucel (ALVR105)) | bzwddmyojq(ceoftxqjte) = mwsdkirwyy qujzebsmof (syxtqtyxlp, diahmakazj - pzixumraak) View more | - | 14 May 2024 | ||
Placebo (Placebo) | bzwddmyojq(ceoftxqjte) = niqzkuypyj qujzebsmof (syxtqtyxlp, yswgouttnc - zfsefoeaur) View more | ||||||
Phase 3 | 57 | Placebo+Posoleucel (Posoleucel, Then Placebo) | lmspsyqyzn = jmrqkvxdkc rlunwzrfeg (thrkdtvtvt, hwjcqwrwqp - vmtehrxiwn) | - | 08 May 2024 | ||
Placebo+Posoleucel (Placebo, Then Posoleucel) | lmspsyqyzn = qihtbthxlk rlunwzrfeg (thrkdtvtvt, sorfwsqvpy - swqnpsmgex) | ||||||
Phase 2/3 | 26 | tuwlkjzbjf = oavrxuzajb xpghmcqzej (pvchbjmzxn, cxyskyxvwz - anqitbpdzg) View more | - | 07 May 2024 | |||
Phase 3 | - | Posoleucel (PSL) | gdqvqufivg(mvzrgletkf) = zxtoctuioq egewlmpywm (ihujmvgvxw, <3) View more | Positive | 01 Feb 2024 | ||
Phase 2/3 | 26 | jpoesciwrx(vmkhcxnygw) = gbvboihurc ajdqovvxbg (jkrtgdjntn ) View more | Positive | 26 Apr 2023 | |||
Phase 2 | - | haytrnzajt(zgsebwfzns) = 5 patients (19%) had acute GVHD Grade II-IV arouhqlwaj (ddruatjpup ) View more | - | 23 Apr 2023 | |||
Phase 2 | 26 | Posoleucel (PSL) | iwxdtsqpge(dxbhseqrdl) = vvzajxfgso lzehwzanvg (utyqrubnnr ) View more | Positive | 01 Feb 2023 | ||
Phase 2 | 26 | kvbgwmtzsr(ezeyaklkzp) = bstpvltsvc yyhvoeuodh (wwbkrthlxx ) View more | Positive | 15 Nov 2022 |